Companies › Amplia Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AMP945 focal adhesion kinase (FAK) inhibitor | PTK2 | Phase 1 | Pancreatic Cancer | Feb 2027 |
| narmafotinib focal adhesion kinase (FAK) inhibitor | FAK | Phase 1 | Pancreatic Cancer Metastatic | Jul 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05355298 | AMP945 | Phase 1 | Pancreatic Cancer | Oncology | Feb 2027 |
| NCT07026279 | narmafotinib | Phase 1 | Pancreatic Cancer Metastatic | Oncology | Jul 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.